FIRST WAVE BIOP.NEW-,0001
FIRST WAVE BIOP.NEW-,0001
Acción · US33749P4081 · FWBI · A3E2F2 (XNCM)
Resumen Indicadores financieros
0,46 EUR
-8,60 % -0,04 EUR
Frankfurt (XNAS) · Precios actuales y gráficos en MoneyPeak
12.06.2025 22:50

Cotizaciones actuales de FIRST WAVE BIOP.NEW-,0001

BolsaTickerMonedaÚltima operaciónPrecioVariación diaria
XNAS: NASDAQ
NASDAQ
ENTO
USD
12.06.2025 22:50
0,53 USD
0,58 USD
-8,60 %

Rendimiento

Día Semana Mes 3 meses 6 meses 1 año 5 años
0,00 % 1,37 % 28,87 % 3,80 % -22,64 % -76,05 % -100,00 %

Perfil de la empresa para FIRST WAVE BIOP.NEW-,0001 Acción

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

Datos de la empresa

Nombre FIRST WAVE BIOP.NEW-,0001
Empresa First Wave BioPharma, Inc.
Símbolo FWBI
Sitio web https://www.firstwavebio.com
Mercado principal XNCM Frankfurt
WKN A3E2F2
ISIN US33749P4081
Tipo de valor Acción
Sector Healthcare
Industria Biotechnology
CEO Mr. James R. Sapirstein M.B.A., R.Ph.
País Estados Unidos de América
Moneda EUR
Empleados 0,0 T
Dirección 777 Yamato Road, 33431 Boca Raton
Fecha de OPV 2016-10-11

Cambios de identificador

Fecha De A
22.09.2021 AZRX FWBI
17.05.2024 FWBI ENTO
22.09.2021 AZRX FWBI

Símbolos de cotización

Nombre Símbolo
NASDAQ ENTO
NASDAQ FWBI

Otras acciones

Los inversores que tienen FIRST WAVE BIOP.NEW-,0001 también tienen las siguientes acciones en su cartera:
AMGEN 15/45
AMGEN 15/45 Bono
HUARONG FIN.2017 17/27MTN
HUARONG FIN.2017 17/27MTN Bono
La plataforma financiera MoneyPeak rastrea y analiza inversiones y carteras. Desde depósitos de valores hasta compras de criptomonedas.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.
Aviso legal Protección de datos Blog Comunidad Comentarios Changelog
Im App Store herunterladen Bei Google Play herunterladen
Todos los derechos reservados © LCP GmbH 2025